Betty S. Chan

ORCID: 0000-0003-0083-282X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Poisoning and overdose treatments
  • Drug-Induced Hepatotoxicity and Protection
  • Cardiac electrophysiology and arrhythmias
  • Pharmacological Effects and Toxicity Studies
  • Potassium and Related Disorders
  • Electroconvulsive Therapy Studies
  • Opioid Use Disorder Treatment
  • Treatment of Major Depression
  • Bipolar Disorder and Treatment
  • Pharmaceutical studies and practices
  • T-cell and B-cell Immunology
  • Forensic Toxicology and Drug Analysis
  • Takotsubo Cardiomyopathy and Associated Phenomena
  • Acute Lymphoblastic Leukemia research
  • Atrial Fibrillation Management and Outcomes
  • Systemic Lupus Erythematosus Research
  • Chronic Myeloid Leukemia Treatments
  • Healthcare Decision-Making and Restraints
  • Immune Cell Function and Interaction
  • Anesthesia and Sedative Agents
  • Renal function and acid-base balance
  • Antibiotics Pharmacokinetics and Efficacy
  • Restraint-Related Deaths
  • Pesticide Exposure and Toxicity
  • Epilepsy research and treatment

Prince of Wales Hospital
2016-2025

Sydney Children's Hospital
2016-2025

UNSW Sydney
2010-2024

Children's Hospital at Westmead
2010-2022

Austin Health
2005-2021

Sydney Children’s Hospitals Network
2021

Lawrence Livermore National Laboratory
1994-2013

Westmead Hospital
1989-2005

Genentech
2001

Royal Prince Alfred Hospital
1997

10.1016/s0736-4679(98)00057-2 article EN Journal of Emergency Medicine 1998-07-01

To investigate the role of IL-6 in systemic lupus erythematosus (SLE), we selectively inhibited lupus-prone NZB/NZW F1(B/W) mice by chronic administration a rat mAb to mouse IL-6. Anti-IL-6 alone elicited an anti-rat response that blocked its biologic effects. circumvent this problem, rendered B/W tolerant anti-CD4 concurrent with first dose anti-IL-6. Thereafter, received weekly injections anti-IL-6 alone. There were two control groups: one group tolerizing regimen along IgG1 (GL113)...

10.1172/jci117373 article EN Journal of Clinical Investigation 1994-08-01

Paracetamol is commonly taken in overdose, with increasing concerns that those taking "massive" overdoses have higher rates of hepatotoxicity and may require doses acetylcysteine. The objective was to describe the clinical characteristics outcomes (≥ 40 g) paracetamol overdoses.Patients were identified through Australian Project, a prospective observational study Poisons Information Centres NSW Queensland, over 3 1.5 years, respectively, retrospectively from three toxicology unit databases...

10.1080/15563650.2017.1334915 article EN Clinical Toxicology 2017-06-23

Introduction Anticholinergic agents are commonly taken in overdose, often causing delirium. The spectrum of anticholinergic delirium ranges from mild agitation to severe behavioural disturbance. Physostigmine is an effective treatment for delirium, but its availability limited. As rivastigmine readily available, it has been used manage delirium; however, there limited research investigating use.

10.1080/15563650.2024.2319854 article EN Clinical Toxicology 2024-02-01

Aims Amlodipine poisoning is a leading cause of cardiovascular medication‐related deaths, commonly managed with high‐dose insulin (HDI) therapy. However, HDI vasodilator that counterproductive in managing vasoplegia. We aim to study therapy patients hypotension following dihydropyridine calcium channel antagonist (CCA) overdose. Methods This retrospective includes adult (≥15 years) deliberate CCA overdose and (mean arterial pressure <65 mmHg or systolic blood <90 mmHg) by two Poisons...

10.1002/bcp.70081 article EN cc-by-nc-nd British Journal of Clinical Pharmacology 2025-04-27

We describe six patients diagnosed with serotonin syndrome after exposure to drugs serotonergic activity Drug interactions occurred as a result of combination tricyclic antidepressants, selective reuptake inhibitors, noradrenaline inhibitors or monoamine oxidase inhibitors. Management included supportive care and the use non-specific antagonists (cyproheptadine, benzodiazepines chlorpromazine). All made uneventful recoveries.

10.5694/j.1326-5377.1998.tb123399.x article EN The Medical Journal of Australia 1998-11-01

Context: We hypothesized that in chronic digoxin toxicity, anti-digoxin antibodies (Fab) would be efficacious binding digoxin, but this may not translate into improved clinical outcomes. Objective: This study aims to investigate changes free concentrations and effects on heart rate potassium poisoning when Fab are given. Materials methods: is a prospective observational study. Patients were recruited if they have been treated with for poisoning. Data was entered standardised form,...

10.1080/15563650.2016.1175620 article EN Clinical Toxicology 2016-04-27

Acetaminophen (APAP) is commonly taken in overdose and can cause acute liver injury via the toxic metabolite NAPQI formed by cytochrome (CYP) P450 pathway. We aimed to evaluate concentrations of APAP metabolites on presentation following an poisoning whether these predicted subsequent onset hepatotoxicity (peak alanine aminotransferase > 1,000 U/L). The Australian Toxicology Monitoring (ATOM) study a prospective observational study, recruiting two poison information centers four toxicology...

10.1002/cpt.2888 article EN cc-by Clinical Pharmacology & Therapeutics 2023-03-15

Objectives This study aimed to determine the impact on practice of applying Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup criteria lithium toxicity. Method We retrospectively examined medical records patients from three hospitals who presented with chronic or acute poisoning a concentration ≥1.3 mmol/L (2008‐2018). determined which were met by and their subsequent course. developed validated method predict if would be >1mmol/L at 36 hours. Results There 111 250 toxic patients....

10.1111/bcp.14212 article EN British Journal of Clinical Pharmacology 2020-01-08

Introduction. Leukocyte function-associated antigen-1 (LFA-1, CD11a) monoclonal antibody (mAb) affects many leukocyte functions without cell depletion. We hypothesized that the use of a humanized, anti-rhesus modified LFA-1 mAb (H2C12) in rhesus monkeys would cause: (1) prolonged heart allograft survival, (2) inhibition primary but not secondary responses, and (3) minimal drug toxicity. Methods Results. Control (n=5) H2C12-treated (n=7) (8–20 mg/kg i.v. on day −1 followed by 10 mg/kg/day)...

10.1097/00007890-200005270-00006 article EN Transplantation 2000-05-01
Coming Soon ...